Literature DB >> 20070387

Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.

Justin W Timbie1, Rodney A Hayward, Sandeep Vijan.   

Abstract

OBJECTIVE: To evaluate the attainability of tight risk factor control targets for three diabetes risk factors and to assess the degree of polypharmacy required. DATA SOURCES/STUDY
SETTING: National Health and Nutrition Examination Survey-III. STUDY
DESIGN: We simulated a strategy of "treating to targets," exposing subjects to a battery of treatments until low-density lipoprotein (LDL)-cholesterol (100 mg/dL), hemoglobin A1c (7 percent), and blood pressure (130/80 mm Hg) targets were achieved or until all treatments had been exhausted. Regimens included five statins of increasing potency, four A1c-lowering therapies, and eight steps of antihypertensive therapy. DATA COLLECTION/EXTRACTION
METHODS: We selected parameter estimates from placebo-controlled trials and meta-analyses. PRINCIPAL
FINDINGS: Under ideal efficacy conditions, 77, 64, and 58 percent of subjects achieved the LDL, A1c, and blood pressure targets, respectively. Successful control depended highly on a subject's baseline number of treatments. Using the least favorable assumptions of treatment tolerance, success rates were 11-17 percentage points lower. Approximately 57 percent of subjects required five or more medication classes.
CONCLUSIONS: A significant proportion of people with diabetes will fail to achieve targets despite using high doses of multiple, conventional treatments. These findings raise concerns about the feasibility and polypharmacy burden needed for tight risk factor control, and the use of measures of tight control to assess the quality of care for diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070387      PMCID: PMC2838154          DOI: 10.1111/j.1475-6773.2009.01075.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  33 in total

1.  From the Food and Drug Administration.

Authors: 
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

2.  Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

Authors:  S D Ross; K S Akhras; S Zhang; M Rozinsky; L Nalysnyk
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

3.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

4.  Contraindications to the use of metformin.

Authors:  G C Jones; J P Macklin; W D Alexander
Journal:  BMJ       Date:  2003-01-04

Review 5.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.

Authors:  M R Law; N J Wald; A R Rudnicka
Journal:  BMJ       Date:  2003-06-28

6.  Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study.

Authors:  Bruce M Psaty; Teri A Manolio; Nicholas L Smith; Susan R Heckbert; John S Gottdiener; Gregory L Burke; Joel Weissfeld; Paul Enright; Thomas Lumley; Neil Powe; Curt D Furberg
Journal:  Arch Intern Med       Date:  2002-11-11

7.  Avoiding pitfalls in chronic disease quality measurement: a case for the next generation of technical quality measures.

Authors:  E A Kerr; S L Krein; S Vijan; T P Hofer; R A Hayward
Journal:  Am J Manag Care       Date:  2001-11       Impact factor: 2.229

8.  Building a better quality measure: are some patients with 'poor quality' actually getting good care?

Authors:  Eve A Kerr; Dylan M Smith; Mary M Hogan; Timothy P Hofer; Sarah L Krein; Martin Bermann; Rodney A Hayward
Journal:  Med Care       Date:  2003-10       Impact factor: 2.983

9.  Improving the reliability of physician performance assessment: identifying the "physician effect" on quality and creating composite measures.

Authors:  Sherrie H Kaplan; John L Griffith; Lori L Price; L Gregory Pawlson; Sheldon Greenfield
Journal:  Med Care       Date:  2009-04       Impact factor: 2.983

10.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28
View more
  11 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  Cost-effectiveness of hypertension therapy according to 2014 guidelines.

Authors:  Andrew E Moran; Michelle C Odden; Anusorn Thanataveerat; Keane Y Tzong; Petra W Rasmussen; David Guzman; Lawrence Williams; Kirsten Bibbins-Domingo; Pamela G Coxson; Lee Goldman
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus.

Authors:  Susan R Kirsh; David C Aron
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 4.  Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.

Authors:  Kasia J Lipska; Harlan Krumholz; Tacara Soones; Sei J Lee
Journal:  JAMA       Date:  2016-03-08       Impact factor: 56.272

5.  Using benefit-based tailored treatment to improve the use of antihypertensive medications.

Authors:  Jeremy Sussman; Sandeep Vijan; Rod Hayward
Journal:  Circulation       Date:  2013-11-04       Impact factor: 29.690

6.  Constructing dynamic treatment regimes with shared parameters for censored data.

Authors:  Ying-Qi Zhao; Ruoqing Zhu; Guanhua Chen; Yingye Zheng
Journal:  Stat Med       Date:  2020-01-17       Impact factor: 2.373

7.  Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial.

Authors:  Michele Heisler; Timothy P Hofer; Julie A Schmittdiel; Joe V Selby; Mandi L Klamerus; Hayden B Bosworth; Martin Bermann; Eve A Kerr
Journal:  Circulation       Date:  2012-05-08       Impact factor: 29.690

8.  Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment: A Modeling Study of Randomized Clinical Trials.

Authors:  Sanjay Basu; Jeremy B Sussman; Rod A Hayward
Journal:  Ann Intern Med       Date:  2017-01-03       Impact factor: 25.391

9.  Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?

Authors:  Grigory Sidorenkov; Jaco Voorham; Dick de Zeeuw; Flora M Haaijer-Ruskamp; Petra Denig
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

10.  Cardiac risk is not associated with hypertension treatment intensification.

Authors:  Jeremy B Sussman; Donna M Zulman; Rodney Hayward; Timothy P Hofer; Eve A Kerr
Journal:  Am J Manag Care       Date:  2012-08       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.